The estimated Net Worth of Thomas W. Beetham is at least $2.14 millió dollars as of 16 September 2021. Mr. Beetham owns over 6,103 units of Kiniksa Pharmaceuticals International Plc stock worth over $338,253 and over the last 6 years he sold KNSA stock worth over $1,801,432. In addition, he makes $0 as Executive Vice President, Chief Legal Officer and Corporate Development és and Secretary at Kiniksa Pharmaceuticals International Plc.
Sign up
Mr. Beetham KNSA stock SEC Form 4 insiders trading
Thomas has made over 6 trades of the Kiniksa Pharmaceuticals International Plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 6,103 units of KNSA stock worth $41,073 on 16 September 2021.
The largest trade he's ever made was selling 49,941 units of Kiniksa Pharmaceuticals International Plc stock on 20 April 2020 worth over $953,873. On average, Thomas trades about 4,853 units every 28 days since 2018. As of 16 September 2021 he still owns at least 13,897 units of Kiniksa Pharmaceuticals International Plc stock.
You can see the complete history of Mr. Beetham stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas Beetham biography
Thomas W. Beetham is Executive Vice President, Chief Legal Officer and Corporate Development, and Secretary of the Company. He has served as our Executive Vice President, Corporate Development and Operations since November 2019 and serves as our Chief Legal Officer, a role he has held since our formation in July 2015, and also serves as our Secretary. Prior to that, Mr. Beetham held various roles at Synageva from October 2013 to June 2015, most recently serving as the Chief Legal Officer and Senior Vice President of Corporate Development, where he led the legal department and was responsible for business development activities. Prior to joining Synageva, from 2011 to 2013, Mr. Beetham was the General Legal Counsel for New England Biolabs, Inc. ("Biolabs"), where he was responsible for legal matters and was a member of Biolabs' global business development team. Before Biolabs, Mr. Beetham held various roles at Genzyme, most recently as the lead corporate attorney responsible for Genzyme's hematology/oncology and multiple sclerosis products, and before that was a business and transactional attorney with the law firm of Palmer & Dodge, LLP. Mr. Beetham holds a J.D. from Boston College Law School, an M.B.A. from Boston College's Carroll School of Management, and a B.A. from the University of Rochester.
How old is Thomas Beetham?
Thomas Beetham is 50, he's been the Executive Vice President, Chief Legal Officer and Corporate Development és and Secretary of Kiniksa Pharmaceuticals International Plc since 2019. There are 10 older and 3 younger executives at Kiniksa Pharmaceuticals International Plc. The oldest executive at Kiniksa Pharmaceuticals International Plc. is Barry Quart, 63, who is the Independent Director.
What's Thomas Beetham's mailing address?
Thomas's mailing address filed with the SEC is C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139.
Insiders trading at Kiniksa Pharmaceuticals International Plc
Over the last 7 years, insiders at Kiniksa Pharmaceuticals International Plc have traded over $11,259,873 worth of Kiniksa Pharmaceuticals International Plc stock and bought 3,912,796 units worth $71,248,379 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., James E Deerfield Mgmt L.P.... és Bros. Advisors Lp667, L.P.B.... On average, Kiniksa Pharmaceuticals International Plc executives and independent directors trade stock every 22 days with the average trade being worth of $1,208,067. The most recent stock trade was executed by Eben Tessari on 1 September 2024, trading 6,463 units of KNSA stock currently worth $157,309.
What does Kiniksa Pharmaceuticals International Plc's logo look like?
Complete history of Mr. Beetham stock trades at Kiniksa Pharmaceuticals International Plc és Magenta Therapeutics Inc
Kiniksa Pharmaceuticals International Plc executives and stock owners
Kiniksa Pharmaceuticals International Plc executives and other stock owners filed with the SEC include:
-
Sanjiv Patel,
Chairman of the Board, Chief Executive Officer -
John Paolini,
Senior Vice President and Chief Medical Officer -
Qasim Rizvi,
Senior Vice President - Operations, Chief Commercial Officer -
Sanj K. Patel,
CEO & Chairman -
Richard Levy,
Independent Director -
Felix Baker,
Lead Independent Director -
Thomas Malley,
Independent Director -
Barry Quart,
Independent Director -
Stephen Biggar,
Independent Director -
Tracey McCain,
Independent Director -
Kimberly Popovits,
Independent Director -
G. Bradley Cole,
Director -
Thomas Beetham,
Executive Vice President, Chief Legal Officer and Corporate Development, and Secretary -
Michael Megna,
Principal Financial Officer, Chief Accounting Officer -
Dr. John F. Paolini,
Sr. VP & Chief Medical Officer -
Mei Jang,
VP of Technical Operations -
Michael R. Megna,
Chief Accounting Officer & VP of Fin. -
Christine Maurer,
Sr. VP of Program Management -
Carsten Boess,
Exec. VP of Corp. Affairs -
Rasmus Holm-Jorgensen,
Sr. VP, Chief Strategy & Portfolio Officer -
Melissa Manno,
Chief HR Officer -
Madelyn Zeylikman,
Gen. Counsel -
Chad Morin,
VP & Chief Compliance Officer -
Mark Ragosa C.F.A.,
Sr. VP & CFO -
Bros. Advisors Lp667, L.P.B...,
-
Asset Management, Lp Chen B...,
-
Stephen F. Mahoney,
President & COO -
James E Deerfield Mgmt L.P....,
-
Carsten Boess,
10% owner -
Chris Heberlig,
EVP & CFO -
Sanj K Patel,
CHAIRMAN & CEO -
Ross Moat,
CHIEF COMMERCIAL OFFICER -
Mark Ragosa,
CHIEF FINANCIAL OFFICER -
Eben Tessari,
CHIEF OPERATING OFFICER -
Arian Pano,
Chief Clinical Dev. Officer